Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs

1] Lung Biology Center, Department of Medicine, University of California, San Francisco, San Francisco, California, USA. [2] Medical Research Council Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.
Nature medicine (Impact Factor: 27.36). 11/2013; 19(12). DOI: 10.1038/nm.3282
Source: PubMed


Myofibroblasts are the major source of extracellular matrix components that accumulate during tissue fibrosis, and hepatic stellate cells (HSCs) are believed to be the major source of myofibroblasts in the liver. To date, robust systems to genetically manipulate these cells have not been developed. We report that Cre under control of the promoter of Pdgfrb (Pdgfrb-Cre) inactivates loxP-flanked genes in mouse HSCs with high efficiency. We used this system to delete the gene encoding αv integrin subunit because various αv-containing integrins have been suggested as central mediators of fibrosis in multiple organs. Such depletion protected mice from carbon tetrachloride-induced hepatic fibrosis, whereas global loss of β3, β5 or β6 integrins or conditional loss of β8 integrins in HSCs did not. We also found that Pdgfrb-Cre effectively targeted myofibroblasts in multiple organs, and depletion of the αv integrin subunit using this system was protective in other models of organ fibrosis, including pulmonary and renal fibrosis. Pharmacological blockade of αv-containing integrins by a small molecule (CWHM 12) attenuated both liver and lung fibrosis, including in a therapeutic manner. These data identify a core pathway that regulates fibrosis and suggest that pharmacological targeting of all αv integrins may have clinical utility in the treatment of patients with a broad range of fibrotic diseases.

Download full-text


Available from: Neil Henderson, May 23, 2014
  • Source
    • "Mice R26R-EYFP (Srinivas et al., 2001), R26R-RFP (Luche et al., 2007), R26R-RFP (Ai14) (Madisen et al., 2010), R26R-Confetti (Snippert et al., 2010), Ck19- CreER (Means et al., 2008), Pdgfrb-Cre (Henderson et al., 2013), and SM22- Cre (Hofmann et al., 2010) mice were used. All mice were kept under barrier "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatocytes provide most liver functions, but they can also proliferate and regenerate the liver after injury. However, under some liver injury conditions, particularly chronic liver injury where hepatocyte proliferation is impaired, liver stem cells (LSCs) are thought to replenish lost hepatocytes. Conflicting results have been reported about the identity of LSCs and their contribution to liver regeneration. To address this uncertainty, we followed candidate LSC populations by genetic fate tracing in adult mice with chronic liver injury due to a choline-deficient, ethionine-supplemented diet. In contrast to previous studies, we failed to detect hepatocytes derived from biliary epithelial cells or mesenchymal liver cells beyond a negligible frequency. In fact, we failed to detect hepatocytes that were not derived from pre-existing hepatocytes. In conclusion, our findings argue against LSCs, or other nonhepatocyte cell types, providing a backup system for hepatocyte regeneration in this common mouse model of chronic liver injury.
    Cell Reports 08/2014; 8(5). DOI:10.1016/j.celrep.2014.07.003 · 8.36 Impact Factor
  • Source
    • "As discussed above, they are genetically determined modifiers, downstream mediators of TGF-β1, and signaling modifiers. They include integrins (such as integrins av), matrix metalloproteases, semaphorin 7a, phosphatase and tensin homolog agonist, and prostaglandin E2 [69,70,71,72,73]. A number of noncoding microRNAs have been identified to directly or indirectly regulate the expression and signaling of TGF-β1 [11]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Pulmonary fibrosis is a fatal progressive disease with no effective therapy. Transforming growth factor (TGF)-β1 has long been regarded as a central mediator of tissue fibrosis that involves multiple organs including skin, liver, kidney, and lung. Thus, TGF-β1 and its signaling pathways have been attractive therapeutic targets for the development of antifibrotic drugs. However, the essential biological functions of TGF-β1 in maintaining normal immune and cellular homeostasis significantly limit the effectiveness of TGF-β1-directed therapeutic approaches. Thus, targeting downstream mediators or signaling molecules of TGF-β1 could be an alternative approach that selectively inhibits TGF-β1-stimulated fibrotic tissue response while preserving major physiological function of TGF-β1. Recent studies from our laboratory revealed that TGF-β1 crosstalk with epidermal growth factor receptor (EGFR) signaling by induction of amphiregulin, a ligand of EGFR, plays a critical role in the development or progression of pulmonary fibrosis. In addition, chitotriosidase, a true chitinase in humans, has been identified to have modulating capacity of TGF-β1 signaling as a new biomarker and therapeutic target of scleroderma-associated pulmonary fibrosis. These newly identified modifiers of TGF-β1 effector function significantly enhance the effectiveness and flexibility in targeting pulmonary fibrosis in which TGF-β1 plays a significant role.
    The Korean Journal of Internal Medicine 05/2014; 29(3):281-290. DOI:10.3904/kjim.2014.29.3.281 · 1.43 Impact Factor
  • Source
    • "Indeed, soluble ACE2 (sACE2) is capable of suppressing integrin signaling mediated by FAK. It has also been shown that integrins are involved in the regulation of fibrosis, suggesting that pharmacologic targeting of all αv integrins may have clinical utility in the treatment of patients with a broad range of fibrotic diseases [51]. It would be interesting to determine whether sarcolemmal ACE2 participates in muscle fiber adhesion. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Duchenne muscular dystrophy (DMD) is the most common inherited neuromuscular disease and is characterized by absence of the cytoskeletal protein dystrophin, muscle wasting, and fibrosis. We previously demonstrated that systemic infusion or oral administration of angiotensin-(1-7) (Ang-(1-7)), a peptide with opposing effects to angiotensin II, normalized skeletal muscle architecture, decreased local fibrosis, and improved muscle function in mdx mice, a dystrophic model for DMD. In this study, we investigated the presence, activity, and localization of ACE2, the enzyme responsible for Ang-(1-7) production, in wild type (wt) and mdx skeletal muscle and in a model of induced chronic damage in wt mice. All dystrophic muscles studied showed higher ACE2 activity than wt muscle. Immunolocalization studies indicated that ACE2 was localized mainly at the sarcolemma and, to a lesser extent, associated with interstitial cells. Similar results were observed in the model of chronic damage in the tibialis anterior (TA) muscle. Furthermore, we evaluated the effect of ACE2 overexpression in mdx TA muscle using an adenovirus containing human ACE2 sequence and showed that expression of ACE2 reduced the fibrosis associated with TA dystrophic muscles. Moreover, we observed fewer inflammatory cells infiltrating the mdx muscle. Finally, mdx gastrocnemius muscles from mice infused with Ang-(1-7), which decreases fibrosis, contain less ACE2 associated with the muscle. This is the first evidence supporting ACE2 as an important therapeutic target to improve the dystrophic skeletal muscle phenotype.
    PLoS ONE 04/2014; 9(4):e93449. DOI:10.1371/journal.pone.0093449 · 3.23 Impact Factor
Show more